INTRODUCTION
============

Endoscopic stenting is used as a definitive treatment, a bridge to surgery, or a palliation of symptoms in patients with various gastrointestinal conditions, including benign or malignant strictures, obstructions, perforations, leaks, and fistulae.^[@B1],[@B2]^ It is a minimally invasive technique and thus is typically suitable for patients who are malnourished and frequently have multiple comorbidities.^[@B2]^

Rigid plastic stents were formerly used for the palliation of malignant strictures related to esophageal cancer.^[@B1]^ The introduction of uncovered self-expanding metal stents (SEMS) in the early 1990s reduced the use of rigid stents^[@B1]^; however, problems such as mucosal hyperplastic reaction (over- or in-growth) with subsequent obstruction of the stent were encountered.^[@B3]^ Therefore, SEMS were fully covered with a silicone membrane to reduce ingrowth of granulation tissue.^[@B4]^ Unfortunately, covered stents are more apt to migrate, are less flexible, and have a shorter radial force. These problems prompted the development of partially covered metal stents with flared uncovered segments at both ends^[@B1],[@B4],[@B5]^ and self-expanding plastic stents (SEPS) to minimize hyperplastic tissue reactions.^[@B6]^ The need for removal is an important disadvantage of SEPS and SEMS.

To overcome these drawbacks, biodegradable stents (BSs) have been developed.^[@B7]^ Goldin et al^[@B8]^ used a poly [l]{.smallcaps}-lactide BS to treat a refractory benign esophageal stricture. The BS disintegrated 6 weeks after placement and obstructed the esophageal lumen. Since 2007, only polydioxanone (SX-ELLA biodegradable esophageal stent; Milady Horakove, Kralove, Czech Republic) BSs have been used for endoscopic placement.^[@B9]^

BSs with body diameters of 18 to 25 mm and lengths of 60 to 135 mm are available, typically with both ends flaring to 23--31 mm to reduce the migration rate. Stent integrity and radial force are maintained for 6--8 weeks after deployment, and complete hydrolytic degradation occurs 11--12 weeks after insertion.^[@B9]^ The biodegradation rate is dependent, not only on stent size and structure, but also in pH, temperature, tissue, and fluid. Acid-suppression therapy slows BS degradation.

We retrospectively investigated the safety and efficacy of the uncovered BS (UBS) for the management of upper gastrointestinal conditions (eg, postoperative leakage and stricture).

MATERIALS AND METHODS
=====================

This was a retrospective study of patients treated endoscopically with UBSs at Bakırköy Sadi Konuk Training and Research Hospital from January 2010 through November 2017. The study protocol was approved by the Ethics Committee of our institute. The demographic characteristics, indications for endoscopic stenting, primary diagnoses, previous surgical interventions, endoscopic procedure duration, stent type, procedural complications, time from surgery to stent placement, and outcomes were recorded.

All endoscopic stenting procedures were performed by an experienced surgeon with the patient under sedation with intravenous propofol. **[Figure 1](#F1){ref-type="fig"}** shows the stent design. Polydioxanone UBSs were placed under fluoroscopic guidance in all patients. First, a guidewire was inserted through the endoscope to the distal part of the pathological segment. Second, a stent of a size appropriate for the patient\'s condition was implanted over the wire after withdrawal of the endoscope. The length of the stricture was measured. After placement, stent position and luminal patency were checked fluoroscopically, with administration of radio-opaque solution. Possible complications were explained to all patients, and written consent was obtained before each procedure.

![Endoscopic view of the uncovered bio-degradable stent (on the left). Flouroscopic image of the stent (on the right).](jls0201637100001){#F1}

After stent placement, clinical, endoscopic, and radiologic outcomes and the timing of initiation of oral feeding were assessed according to the indication for endoscopic stenting. The stent positions were endoscopically checked in all patients at 2 and 6 month. In patients with gastric tumors, endoscopic controls were performed annually. No endoscopic follow-up was performed in patients who remained asymptomatic.

Technical success was defined as successful stent deployment. Clinical success was defined as healing of the postoperative leak or stricture and restoration of oral food intake after UBS application without other intervention.

RESULTS
=======

This study involved 13 patients, 7 (54%) of whom were men. The ages of the patients ranged from 21 to 82 (mean, 46) years.

The indications for stent placement were postoperative leakage and stricture in 9 and 4 patients, respectively. The primary diagnoses were obesity in 7 patients, gastric cancer in 5, and peptic ulcer in 1. Postoperative proximal gastric leakage developed after sleeve gastrectomy in 5 patients. Three had anastomotic leakage after total gastrectomy. One patient with postoperative leakage from the gastroesophageal junction, who had undergone vagotomy and pyloroplasty secondary to massive bleeding associated with duodenal ulcer, presented with a tracheal-esophageal fistula.

UBSs were placed in 6 patients with postoperative leak after failure of 14 days of conservative treatment, which comprised parenteral nutrition, full fasting, and intravenous antibiotics. Three of the 9 patients with postoperative leakage had undergone unsuccessful interventions before UBS placement. One of them had undergone a mini gastric bypass because of proximal gastric leakage after sleeve gastrectomy. Endoscopic closure of anastomotic leakage using an over-the-scope clip device was attempted in the second patient. Placement of a self-expandable metal stent had been unsuccessful in the third patient.

The strictures were located at the proximal suture line after sleeve gastrectomy in 2 patients and at the anastomosis after total gastrectomy in 2 patients. These patients were able to tolerate liquids only. The median length of the strictures was 1 (range, 1--3) cm. All patients with stricture had multiple endoscopic dilation sessions before stent application. Regarding stent dimensions, 31 × 100-mm stents were placed in 6 patients, with 28 × 80-mm stents in 4, 23 × 80-mm stents in 2, and a 30 × 80-mm stent in 1. The mean procedure time was 20 (range, 15--30) min. In 2 patients with stricture, balloon dilation was necessary to advance the guidewire beyond the stenotic segment. Stent insertion was successful at the first attempt in all patients (technical success rate, 100%). No intraprocedural complications occurred.

The average time to stent placement after surgery was 35 (range, 17--125) and 166 (range, 153--185) days for patients with postoperative leakage and stricture, respectively.

After stent placement, all patients except those who underwent total gastrectomy received acid-suppression therapy to prevent reflux disease. Patients with postoperative leakage underwent a fluoroscopic check-up with oral administration of contrast medium 3 to 5 days after stent deployment. In 1 patient, ongoing contrast leakage through the bioabsorbable thread of the stent was detected during the check-up. This patient underwent deployment of a covered metallic stent over the previous stent. In another patient with chronic gastric fistula, total gastrectomy was performed 10 months after stent placement. Therefore, in 2 of 13 patients UBS placement did not resolve gastric leakage (clinical success rate, 85%). Except in those cases, no further procedure was required.

Patients with postoperative leakage started oral intake after persistent leakage was ruled out by clinical and radiologic evaluations. The mean duration of hospital stay after placement of a UBS in those patients was 10 (range, 7--16) days. Patients with stricture tolerated liquids immediately after stent placement and subsequently consumed solids. They were discharged later on the day of stent placement.

The mean follow-up duration was 50 (range, 24--76) months. Four patients with gastric cancer died. After stent placement, retrosternal pain, the sensation of having a foreign object in the body, and drooling occurred in all patients. Retrosternal pain was responsive to analgesics and ceased in 10--15 days. The foreign-object feeling and drooling lasted for several weeks. Aversion to water developed in 8 patients, lasted for 2 months, and resolved spontaneously. Six patients had nausea for a few days, which was treated with metoclopramide. As for endoscopic surveillance, partial and complete stent degradation, along with mild mucosal hypertrophy, were seen in all but 1 of the patients at the 2- and 6-month follow-ups, respectively. In 1 patient, mucosal hypertrophy was excessive, appearing as pseudopolyps, but they were asymptomatic and did not require intervention. Patient and surgical information is shown in **[Table 1](#T1){ref-type="table"}**.

###### 

Characteristics of the Patients and Surgical Procedures

  No.   Gender   Age   Cause of UBS Application            Primary Diagnosis   Previous Surgery         Pre-UBS Therapy          Post-UBS Therapy                                Procedure Time (minutes)   Stent Type   Time to stent placement (days)   Duration of Hospital Stay After Stenting (days)   Follow-up (months)   Complications
  ----- -------- ----- ----------------------------------- ------------------- ------------------------ ------------------------ ----------------------------------------------- -------------------------- ------------ -------------------------------- ------------------------------------------------- -------------------- ----------------------------------------
  1     M        36    Proximal gastric leak               Obesity             Sleeve gastrectomy       --                       --                                              25                         23×80        37                               15                                                76                   RP, FOF, D, N, MH
  2     M        40    Proximal gastric leak               Obesity             Sleeve gastrectomy       Metal stent              --                                              25                         31×100       25                               8                                                 64                   RP, FOF, D, N, MH
  3     F        43    Proximal gastric leak               Obesity             Sleeve gastrectomy       --                       --                                              15                         23×80        20                               9                                                 63                   RP, FOF, D, N, MH
  4     F        22    Proximal gastric leak               Obesity             Sleeve gastrectomy       Mini gastric bypass      Total gastrectomy and R-Y esophagojejunostomy   20                         31×100       125                              7                                                 29                   RP, FOF, D, N
  5     F        21    Proximal gastric leak               Obesity             Sleeve gastrectomy       OTSC                     --                                              30                         31×100       27                               7                                                 38                   RP, FOF, D, RW, MH
  6     M        55    Anastomotic leak                    Gastric cancer      Total gastrectomy        --                       Covered metal stent                             15                         31×100       21                               14                                                48                   RP, FOF, D, RW, MH
  7     M        71    Anastomotic leak                    Gastric cancer      Total gastrectomy        --                       --                                              15                         31×100       18                               8                                                 36                   RP, FOF, D, RW, MH
  8     F        82    Anastomotic leak                    Gastric cancer      Total gastrectomy        --                       --                                              15                         28×80        17                               10                                                24                   RP, FOF, D, MH
  9     F        54    Tracheal-esophageal fistula         Peptic ulcer        Vagotomy -pyloroplasty   --                       --                                              20                         28×80        32                               16                                                59                   RP, FOF, D, N, RW, MH
  10    F        31    Stricture at proximal suture line   Obesity             Sleeve gastrectomy       Endoscopic dilatations   --                                              20                         28×80        153                              Same day                                          63                   RP, FOF, D, N, RW, MH and Pseudopolyps
  11    M        44    Stricture at proximal suture line   Obesity             Sleeve gastrectomy       Endoscopic dilatations   --                                              15                         30×80        160                              Same day                                          57                   RP, FOF, D, RW, MH
  12    M        69    Anastomotic stricture               Gastric cancer      Total gastrectomy        Endoscopic dilatations   --                                              20                         31×100       185                              Same day                                          46                   RP, FOF, D, RW, MH
  13    M        39    Anastomotic stricture               Gastric cancer      Total gastrectomy        Endoscopic dilatations   --                                              15                         28×80        166                              Same day                                          54                   RP, FOF, D, RW, MH

D, drooling; FOF, foreign object feeling; MH, mucosal hypertrophy; N, nausea; RP, retrosternal pain; RW, rejection of water.

DISCUSSION
==========

We report our clinical experience with UBS for postoperative anastomotic or staple line leak, fistula, and stricture. Technical success was achieved in all patients. Eleven of the 13 patients achieved complete resolution of the leak and stricture after UBS deployment and symptom relief after stent degradation.

All surgical interventions have a risk of complications. Postoperative leaks can be fatal and occur after 1%--10% and 1%--3% of total and sleeve gastrectomies, respectively.^[@B10][@B11][@B14]^ Various factors, including technical errors, stapler misfiring, poor blood supply, and increased intragastric pressure, are related to postoperative leakage. Patients with unstable parameters require prompt reoperation for washout and drainage and possibly also debridement and suturing of the orifice, if appropriate. The optimal management of postoperative leaks is controversial because of the lack of standardized treatment protocols.^[@B15]^ Extensive nutritional support and intravenous antibiotic infusion are important components of management. Generally, enteral nutrition is preferred over total parenteral nutrition during the postoperative period because it provides a better response to infectious complications, allows better maintenance of bowel function, reduces hepatic steatosis, and costs less. Despite these advantages, during the early postoperative period, which is often associated with bowel hypoperistalsis, parenteral nutrition is generally used in patients with newly placed stents to decrease intraluminal secretions and bowel pressure. Before UBS application, we made conservative treatment with parenteral nutrition in all patients with leakage but it persisted. In stable patients in whom conservative therapy has failed, endoscopic stenting is a valid treatment option for acute leaks, together with adequate drainage.^[@B16]^ Stent placement can reduce the time from procedure to starting oral intake, morbidity, and duration of hospital stay compared with surgical intervention. Stents may also facilitate correction of the sleeve axis in cases of gastric twisting.^[@B17]^ There is no consensus as to which type of stent is optimal. Use of covered metal stents to stop benign upper gastrointestinal leaks, perforations, and fistulae has a success rate of 72%--79%.^[@B18],[@B19]^ Alazmi et al^[@B17]^ found that metal and plastic stents have a 76% success rate for post--sleeve gastrectomy leaks. Simon et al^[@B20]^ reported that earlier endoscopic stent placement (\<3 wk after leak diagnosis) accelerates healing in patients with gastric leakage after sleeve gastrectomy. BSs are used increasingly frequently, as they do not have to be removed and are effective for treating leaks after total and sleeve gastrectomy.^[@B1],[@B20]^ In this study, UBSs promoted complete healing by inducing a fibrous reaction in 11 of 13 patients.

Postoperative strictures affect 2%--5% and 1%--3% of patients after total and sleeve gastrectomy, respectively.^[@B21],[@B22]^ The following factors are associated with postoperative stricture development: technical errors, decreased vascularization, foreign-body reaction, inflammation after small anastomotic leaks, and radiotherapy. These strictures are complex and usually require multiple endoscopic dilations with bougies or balloons.^[@B21]^ However, several novel techniques have become available: incision of the stenosis with electrocautery, intralesional steroid injection, and stent placement.^[@B2],[@B23]^ Van Hooft et al^[@B24]^ reported that BS placement was an effective 1-step treatment for postsurgical esophagogastric anastomotic strictures in 6 of 10 patients. By contrast, a recent meta-analysis of the clinical outcomes of plastic and metal stents compared to BSs in patients with benign esophageal strictures reported a pooled clinical success rate of 40.5%, which did not differ among the types of stent.^[@B25]^ Placement of UBSs was successful in our patients who had stricture, with no need for reintervention during a 50-month follow-up. BSs facilitate tissue remodeling, resulting in recovery of the stricture. Resolution of postoperative inflammation and the prolonged dilatory effects of the stent may be important factors for maintaining an adequate lumen.

In a case series, Ham and Kim^[@B26]^ reported a biodegradable stent migration rate of 0% to 22%. The uncovered design of BSs enables the stent to become embedded in the underlying tissue, which reduces the migration rate but causes reactive tissue hyperplasia, which can lead to severe stent stenosis and recurrent dysphagia. Karakan et al^[@B27]^ reported that 57% of their patients experienced tissue hyperplasia. To prevent this development, drug-eluting (such as rapamycin and paclitaxel) stents have been evaluated.^[@B28]^ In this study, mild mucosal hypertrophy occurred in all patients, except 1, whose mucosal hypertrophy was excessive and appeared as pseudopolyps; fortunately, the condition did not have clinical consequences. Thoracic pain, the sensation of having a foreign object in the body, perforation, and bleeding are other complications of BS placement.^[@B9]^ Retrosternal pain was a common finding after stent placement and was associated with gradual expansion of the stent. No stent migration occurred. Aversion to water was another complication of stent treatment, but the mechanism is unknown.

Although biodegradable stents are more expensive than other plastic or metal stents, they could be cost effective because there is no need for removal. Sometimes, repeated endoscopic procedures are necessary to remove other stents, resulting in loss of workforce, time, and money.

In conclusion, the optimal type of endoscopic stent for postsurgical upper gastrointestinal tract issues is unclear. The optimal stent would be easy to place and to retrieve, would use a small-calibre delivery mechanism, would not migrate, and would induce minimal tissue reaction. Our results indicate that the placement of UBSs for the management of postoperative leaks and strictures is technically simple, safe, and clinically effective. Larger randomized trials that compare the various types of stent are necessary to confirm our results.

[^1]: Disclosure: none reported.
